发明名称 |
TREATMENT OF TAUOPATHIES WITH mGluR5 ANTAGONISTS |
摘要 |
The treatment of abnormal hyperphosphorylation of tau in brains of patients with metabotropic glutamate receptor 5 (mGluR5) antagonists. The treatment uses the signaling pathway in which the inhibition of protein phosphatase 2A (PP2A) through phosphorylation of its catalytic subunit PP2Ac at Tyr307 is induced by the activation of metabotropic glutamate receptor 5 (mGluR5) and leads to hyperphosphorylation of tau. The mGluR5-PP2A axis has a central role in neurofibrillary degeneration and thus is be a therapeutic target for the treatment of tauopathies. |
申请公布号 |
US2016038471(A1) |
申请公布日期 |
2016.02.11 |
申请号 |
US201514818515 |
申请日期 |
2015.08.05 |
申请人 |
The Research Foundation for Mental Hygiene, Inc. |
发明人 |
Iqbal Khalid |
分类号 |
A61K31/44;A61K9/00 |
主分类号 |
A61K31/44 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating a patient having a tauopathy, comprising the step of administering a pharmaceutically effective amount of an mGluR5 antagonist. |
地址 |
Menands NY US |